Beech Biotech SA

Beech Biotech SA is dedicated to pioneering breakthrough treatments for preeclampsia and other pregnancy complications. With a focus on innovative biological solutions, Beech Biotech is committed to addressing the critical unmet need for medicines that treat the mother without exposing the fetus to additional risk. Beech Biotech's approach centers on developing "Mother Only" monoclonals, utilizing a patented modification that prevents antibodies from crossing the placenta.

Beech Biotech's lead asset, MOm303, is designed to bind and eliminate maternal sFlt-1, a known cause of vascular breakdown in preeclampsia. By releasing placental growth factor, MOm303 aims to restore the healthy balance of these factors, potentially prolonging pregnancy and reducing the consequences of preterm birth. Beech Biotech is positioned to make a significant impact on maternal and infant health worldwide.

Beech Biotech SA is committed to innovation and excellence in biotechnology research, focusing on delivering solutions that improve outcomes for mothers and babies globally. We invite the manager of Beech Biotech SA to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial development.